Superior protein quality control in a user-friendly format
The Agilent 2100 Bioanalyzer plus the Agilent High Sensitivity Protein 250 Kit automatically detects and quantifies protein impurities down to 0.05% for superior Protein QC in a production-ready method!
The Agilent 2100 Bioanalyzer together with the Agilent High Sensitivity Protein 250 Kit offers unsurpassed speed, sensitivity and reproducibility for superior protein QC in a production-ready method. It detects and quantifies low concentrated impurities next to massive main components – down to 0.05% and below. This meets the ICH guideline Q3B(R2) on Impurities in New Drug Products!
Built on Agilent’s industry leading lab-on-a-chip platform, the 2100 Bioanalyzer offers:
- Sensitivity and linear dynamic range – silver stain sensitivity down to 1 pg/μL of labeled protein on chip and 4 orders of magnitude in linear dynamic range.
- Fast results – complete automated analysis of 10 samples in 30 minutes.
- Reproducibility qualitative, user-independent and digital data.
- Ease of use standardized assay, pre-packaged reagent kits.
- 21 CFR Part 11 compliance validated reagents, software, and compliance services to meet all GMP/GLP needs.
The High Sensitivity Protein 250 kit provides the first microfluidic assay for protein detection in the low picogram range. Therefore, the kit is perfectly suited to solve typical protein QA/QC questions and to comply with ICH and FDA guidelines.
Learn more about the Agilent 2100 Bioanalyzer.
Request Agilent’s Protein QC Application CD!
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
